Vertex Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$2,964,700
$2,770,200
$2,912,000
$2,771,900
Gross Profit
2,557,200
2,407,200
2,488,600
2,379,300
EBITDA
1,422,300
781,800
1,184,400
1,284,800
EBIT
1,286,700
733,400
1,137,900
1,231,600
Net Income
1,032,900
646,300
913,000
1,045,400
Net Change In Cash
2,964,700
2,770,200
2,912,000
2,771,900
Free Cash Flow
927,400
778,200
492,000
1,302,100
Cash
4,972,200
4,674,700
4,569,600
5,239,200
Basic Shares
258,900
259,500
260,500
261,000

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$11,020,100
$9,869,200
$8,930,700
$7,574,400
Gross Profit
9,489,600
8,607,000
7,850,400
6,670,200
EBITDA
486,300
4,605,200
4,435,500
2,917,500
EBIT
280,500
4,423,900
4,287,200
2,791,900
Net Income
-535,600
3,619,600
3,322,000
2,342,100
Net Change In Cash
11,020,100
9,869,200
8,930,700
7,574,400
Cost of Revenue
3,741,100
824,600
Free Cash Flow
-790,300
3,278,900
3,925,200
2,408,500
Cash
4,569,600
10,369,100
10,504,000
6,795,000
Basic Shares
257,900
260,500
259,100
259,899

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$4.52
2025-03-31
$4.06
2024-12-31
$3.98